Shore Capital Reaffirms Buy Rating for Uniphar (LON:UPR)

Uniphar (LON:UPR - Get Free Report)'s stock had its "buy" rating restated by Shore Capital in a research note issued on Tuesday, Marketbeat Ratings reports.

Uniphar Price Performance

Shares of UPR traded down GBX 2.50 ($0.03) during trading hours on Tuesday, reaching GBX 195 ($2.42). 15,791 shares of the company traded hands, compared to its average volume of 20,640. The stock has a fifty day simple moving average of GBX 176.10 and a 200 day simple moving average of GBX 198.68. Uniphar has a fifty-two week low of GBX 163 ($2.02) and a fifty-two week high of GBX 256 ($3.18). The stock has a market capitalization of £532.39 million, a PE ratio of 1,392.86 and a beta of 0.75. The company has a quick ratio of 0.60, a current ratio of 0.90 and a debt-to-equity ratio of 119.43.

Uniphar Company Profile

Headquartered in Dublin, Ireland Uniphar plc is a diversified healthcare services business servicing the requirements of more than 200 multinational pharmaceutical and medical technology manufacturers across three divisions – Commercial & Clinical, Product Access and Supply Chain & Retail. With a workforce of more than 2,000, the Group is active in Ireland, the UK and the Benelux.